Patrick Forde
Cited by
Cited by
Neoadjuvant PD-1 blockade in resectable lung cancer
PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ...
New England Journal of Medicine 378 (21), 1976-1986, 2018
Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer
PM Forde, J Spicer, S Lu, M Provencio, T Mitsudomi, MM Awad, E Felip, ...
New England Journal of Medicine 386 (21), 1973-1985, 2022
Genome-wide cell-free DNA fragmentation in patients with cancer
S Cristiano, A Leal, J Phallen, J Fiksel, V Adleff, DC Bruhm, SŲ Jensen, ...
Nature 570 (7761), 385-389, 2019
Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer
V Anagnostou, KN Smith, PM Forde, N Niknafs, R Bhattacharya, J White, ...
Cancer discovery 7 (3), 264-276, 2017
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
TR Cottrell, ED Thompson, PM Forde, JE Stein, AS Duffield, ...
Annals of Oncology 29 (8), 1853-1860, 2018
Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations
AB Schrock, GM Frampton, J Suh, ZR Chalmers, M Rosenzweig, ...
Journal of Thoracic Oncology 11 (9), 1493-1502, 2016
Pneumonitis in non–small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors
K Suresh, KR Voong, B Shankar, PM Forde, DS Ettinger, KA Marrone, ...
Journal of Thoracic Oncology 13 (12), 1930-1939, 2018
Antagonists of PD-1 and PD-L1 in cancer treatment
EJ Lipson, PM Forde, HJ Hammers, LA Emens, JM Taube, SL Topalian
Seminars in oncology 42 (4), 587-600, 2015
Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non–small cell lung cancer
B Shankar, J Zhang, AR Naqash, PM Forde, JL Feliciano, KA Marrone, ...
JAMA oncology 6 (12), 1952-1956, 2020
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
JX Caushi, J Zhang, Z Ji, A Vaghasia, B Zhang, EHC Hsiue, BJ Mog, ...
Nature 596 (7870), 126-132, 2021
Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma
L Chen, J Douglass, L Kleinberg, X Ye, AE Marciscano, PM Forde, ...
International Journal of Radiation Oncology* Biology* Physics 100 (4), 916-925, 2018
Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer
V Anagnostou, PM Forde, JR White, N Niknafs, C Hruban, J Naidoo, ...
Cancer research 79 (6), 1214-1225, 2019
Epigenetic therapy inhibits metastases by disrupting premetastatic niches
Z Lu, J Zou, S Li, MJ Topper, Y Tao, H Zhang, X Jiao, W Xie, X Kong, ...
Nature 579 (7798), 284-290, 2020
Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancer
MJ Bott, SC Yang, BJ Park, PS Adusumilli, VW Rusch, JM Isbell, ...
The Journal of thoracic and cardiovascular surgery 158 (1), 269-276, 2019
A clinical review of treatment outcomes in glioblastoma multiforme—the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more …
K Rock, O McArdle, P Forde, M Dunne, D Fitzpatrick, B O'Neill, C Faul
The British journal of radiology 85 (1017), e729-e733, 2012
Detection and characterization of lung cancer using cell-free DNA fragmentomes
D Mathios, JS Johansen, S Cristiano, JE Medina, J Phallen, KR Larsen, ...
Nature communications 12 (1), 5060, 2021
PD-1 blockade in anaplastic thyroid carcinoma
J Capdevila, LJ Wirth, T Ernst, S Ponce Aix, CC Lin, R Ramlau, MO Butler, ...
Journal of Clinical Oncology 38 (23), 2620-2627, 2020
Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumors
G Curigliano, H Gelderblom, N Mach, T Doi, D Tai, PM Forde, ...
Clinical Cancer Research 27 (13), 3620-3629, 2021
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
TJ Braaten, JR Brahmer, PM Forde, D Le, EJ Lipson, J Naidoo, ...
Annals of the rheumatic diseases 79 (3), 332-338, 2020
Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 …
B Ricciuti, X Wang, JV Alessi, H Rizvi, NR Mahadevan, YY Li, A Polio, ...
JAMA oncology 8 (8), 1160-1168, 2022
The system can't perform the operation now. Try again later.
Articles 1–20